New Pancreatic Cancer Drug Costs $39,800 Monthly: What to Know
The Food and Drug Administration has approved daraxonrasib, an oral tablet branded as Rasonque, for adults with metastatic pancreatic adenocarcinoma, providing a groundbreaking treatment that reduced the risk of death by 60% in phase 3 trials, according to Revolution Medicines and BioPharma Dive. Patients receiving the medication lived 13.2 months, compared to 6.7 months for … Read more